

Surendra K Shukla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9331563/publications.pdf>

Version: 2024-02-01

24
papers

1,362
citations

516561

16
h-index

610775

24
g-index

24
all docs

24
docs citations

24
times ranked

2429
citing authors

#	ARTICLE	IF	CITATIONS
1	CD73 induces GM-CSF/MDSC-mediated suppression of T cells to accelerate pancreatic cancer pathogenesis. <i>Oncogene</i> , 2022, 41, 971-982.	2.6	29
2	Visceral adipose tissue remodeling in pancreatic ductal adenocarcinoma cachexia: the role of activin A signaling. <i>Scientific Reports</i> , 2022, 12, 1659.	1.6	8
3	Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression. <i>Gastroenterology</i> , 2021, 161, 1584-1600.	0.6	50
4	IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2457-2468.	1.9	2
5	Metabolic Alterations in Pancreatic Cancer Progression. <i>Cancers</i> , 2020, 12, 2.	1.7	38
6	JNK signaling contributes to skeletal muscle wasting and protein turnover in pancreatic cancer cachexia. <i>Cancer Letters</i> , 2020, 491, 70-77.	3.2	27
7	SIRT1-NOX4 signaling axis regulates cancer cachexia. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	43
8	The Synergistic Effect of an ATP-Competitive Inhibitor of mTOR and Metformin on Pancreatic Tumor Growth. <i>Current Developments in Nutrition</i> , 2020, 4, nzaa131.	0.1	6
9	Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia. <i>Cancer Letters</i> , 2020, 484, 29-39.	3.2	39
10	Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy. <i>Cancers</i> , 2019, 11, 1327.	1.7	27
11	Evaluating the Metabolic Alterations in Pancreatic Cancer. <i>Methods in Molecular Biology</i> , 2019, 1882, 221-228.	0.4	4
12	Molecular and Physiological Evaluation of Pancreatic Cancer-Induced Cachexia. <i>Methods in Molecular Biology</i> , 2019, 1882, 321-333.	0.4	4
13	Microscale Gene Expression Analysis of Tumor-Associated Macrophages. <i>Scientific Reports</i> , 2018, 8, 2408.	1.6	8
14	Hypoxia-Mediated In Vivo Tumor Glucose Uptake Measurement and Analysis. <i>Methods in Molecular Biology</i> , 2018, 1742, 107-113.	0.4	8
15	Transcriptional Profiling Using RNA-Seq to Study Hypoxia-Mediated Gene Regulation. <i>Methods in Molecular Biology</i> , 2018, 1742, 55-66.	0.4	3
16	GOT1-mediated anaplerotic glutamine metabolism regulates chronic acidosis stress in pancreatic cancer cells. <i>Cancer Letters</i> , 2017, 400, 37-46.	3.2	76
17	MUC1-Mediated Metabolic Alterations Regulate Response to Radiotherapy in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5881-5891.	3.2	73
18	De Novo Lipid Synthesis Facilitates Gemcitabine Resistance through Endoplasmic Reticulum Stress in Pancreatic Cancer. <i>Cancer Research</i> , 2017, 77, 5503-5517.	0.4	143

#	ARTICLE	IF	CITATIONS
19	MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. <i>Cancer Cell</i> , 2017, 32, 71-87.e7.	7.7	373
20	EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer. <i>Biomacromolecules</i> , 2016, 17, 301-313.	2.6	41
21	Role of Curcumin in Common Musculoskeletal Disorders: a Review of Current Laboratory, Translational, and Clinical Data. <i>Orthopaedic Surgery</i> , 2015, 7, 222-231.	0.7	42
22	MUC16-mediated activation of mTOR and c-MYC reprograms pancreatic cancer metabolism. <i>Oncotarget</i> , 2015, 6, 19118-19131.	0.8	61
23	Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth. <i>Oncotarget</i> , 2015, 6, 41146-41161.	0.8	75
24	Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. <i>Cancer & Metabolism</i> , 2014, 2, 18.	2.4	182